Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2002-02-28
2009-06-02
Spector, Lorraine (Department: 1647)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S192100, C424S193100, C424S195110, C424S172100, C424S198100, C435S069100, C435S069520, C530S351000
Reexamination Certificate
active
07541040
ABSTRACT:
The invention provides uses and methods for alleviating respiratory tract symptoms of allergy, asthma, and of viral, bacterial, fungal and parasitic infections by shifting inappropriate TH2 responses to TH1 responses by administering IL-13 receptor-targeted immunotoxins to the respiratory tract.
REFERENCES:
patent: 5919456 (1999-07-01), Puri et al.
patent: 6664227 (2003-12-01), Wynn et al.
patent: 1270595 (2003-01-01), None
patent: WO 96/29417 (1996-09-01), None
patent: WO 00/04926 (2000-02-01), None
“The Cytokine FactsBook”, 2nded., K.A. Fitzgerald et al., Academic Press New York, 2001; pp. 105-109 and frontspiece.
Blease, K., et al., “IL-13 fusion cytotoxin ameliorates chronic fungal-induced allergic airway disease in mice,” 2001,J. Immunol., vol. 167(11), pp. 6583-6592.
Blease, K., et al., “Therapeutic effect of IL-13 immunoneutralization during chronic experimental fungal asthma,” 2001,J. Immunol., vol. 166, pp. 5219-5224.
Blease, K., et al., “Stat6-deficient mice develop airway hypperresponsiveness and peribronchial fibrosis during chronic fungal asthma,” 2002,Am. J. Pathol., vol. 160(2), pp. 481-490.
Blümchen, K., et al., Interleukin-5: a novel target for asthma therapy, 2001,Expert Opinion in Biological Therapy, vol. 1(3), pp. 433-453. (Abstract provided).
Chomarat, P. and J. Banchereau, “Interleukin-4 and interleukin-13: their similarities and discrepancies,” 1998,Int. Rev. Immunol., vol. 17(1-4), pp. 1-52.
Corry, D.B., “IL-13 in allergy: home at last,” 1999,Curr. Opin. Immunol., 1999, vol. 11(6), pp. 610-614.
de Vries, J.E., “The role of IL-13 and its receptor in allergy and inflammatory responses,” 1998,J. Allergy Clin. Immunol., vol. 102(2), pp. 165-169.
Grünig, G., et al., “Requirement for IL-13 independently of IL-4 in experimental asthma,” 1998,Science, vol. 282, pp. 2261-2263.
Husain, S.R. and P.K. Puri, “Interleukin-13 fusion cytotoxin as a potent targeted agent for AIDS-Kaposi's sarcoma xenograft,” 2000,Blood, vol. 95, pp. 3506-3513.
Husain, S.R., et al., “Interleukin-13 receptor as a unique target for anti-glioblastoma therapy,” 2001,Int. J. Cancer, vol. 92, pp. 168-175.
Kaminski, A., et al., “IL-2 and IL-4 specific and control antisense oligonucleotides can induce apoptosis of the malignant B-CLL cell,” 2000,Blood, vol. 96(11, pt. 2), pp. 276b-277b. (Abstract provided).
Kawakami, K., et al., “Interleukin-13 receptor targeted cancer therapy in an immunodeficient animal model of human head and neck cancer,” 2001,Cancer Res., vol. 61, pp. 6194-6200.
Lamkhioued, B. and P.M. Renzi, “Inhibition of IL-4a and IL-13a′ receptors by antisense phosphorothioate oligonucleotides suppress IL-4-induced human IgE production and Th2 differentiation,” 2000,J. Allergy Clin. Immunol., vol. 105(1-2), p. S179. (Abstract provided).
McKenzie, A.N., “Regulation of T helper type 2 cell immunity by interleukin-4 and interleukin-13,” 2000,Pharmacol. Ther., vol. 88(2), pp. 143-151.
Oshima, Yasou and Raj. K. Puri, “Characterization of a powerful high affinity antagonist that inhibits biological activities of human interleukin-” 2001,J. Biol. Chem., vol. 276, pp. 15185-15191.
Weltman, J.K. and A.S. Karim, “IL-5: biology and potential therapeutic applications,” 2000,Expert Opinion on Investigational Drugs, vol. 9(3), pp. 491-496. (Abstract provided).
Wills-Karp, M., et al., “Interleukin-13: central mediator of allergic asthma,” 1998,Science, vol. 282, pp. 2258-2261.
Zhu, Z., et al., Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production, 1999,J. Clin. Invest., vol. 103, pp. 779-788.
Hogaboam Cory M.
Jakubzick Claudia
Kunkel Steven L.
Puri Raj K.
Spector Lorraine
The Regents of the University of Michigan, Office of Technology
The United States of America as represented by the Department of
Townsend and Townsend / and Crew LLP
LandOfFree
Chimeric molecule for the treatment of th2-like cytokine... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chimeric molecule for the treatment of th2-like cytokine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chimeric molecule for the treatment of th2-like cytokine... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4068924